Browsing Tag
Sanofi SA
2 posts
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.
Sanofi’s second chance: Why Europe is warming up to Rezurock after initial CHMP rejection
Sanofi’s Rezurock secures EU conditional approval recommendation for chronic GVHD. Find out what changed and how this could reshape rare disease care.